By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third-quarter revenues jumped 50 percent, easily beating analysts' consensus estimate.

The San Diego-based sequencing and array technologies firm reported total revenues of $237.3 million for the three-month period ended Oct. 3, compared to $158.4 million for the third quarter of 2009. Analysts had expected the firm to post revenues of $218.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.